

## Product datasheet for TL313850

## **CLN3 Human shRNA Plasmid Kit (Locus ID 1201)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** CLN3 Human shRNA Plasmid Kit (Locus ID 1201)

Locus ID: 1201

BTN1; BTS; INCL Synonyms:

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

CLN3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1201). Components:

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

NM 000086, NM 001042432, NM 001286104, NM 001286105, NM 001286109, RefSeq:

NM 001286110, NM 000086.1, NM 000086.2, NM 001042432.1, NM 001286105.1,

NM 001286109.1, NM 001286110.1, NM 001286104.1, BC004433, BC004433.1, BC002394, BC111068, NM 001286105.2, NM 001286110.2, NM 001042432.2, NM 001286104.2,

NM 001286109.2

**UniProt ID:** Q13286

**Summary:** This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well

> as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses

(NCLs). Many alternatively spliced transcript variants have been found for this gene.

[provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact techsupport@origene.com.

If you need a special design or shRNA sequence, please utilize our custom shRNA service.



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com



## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).